Introduction 

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, contributing to millions of deaths each year. However, most colorectal cancers arise from benign growths known as tubular adenomas, which are commonly detected during screening procedures. Not all adenomas progress to cancer, but some can become malignant over time, making it essential for medical professionals to identify high-risk cases early. Early detection is crucial because it can lead to prompt intervention and significantly reduce the risk of developing full-blown cancer.

Molecular biomarkers have emerged as a promising tool in assessing the risk of cancer progression in patients with tubular adenomas. These biomarkers, indicators of underlying molecular or genetic changes, can provide valuable insights into which adenomas are more likely to become malignant. By recognising these risk factors, physicians can more accurately forecast results and make well-informed choices about monitoring and treatment.

Understanding Tubular Adenomas

What Are Tubular Adenomas?

Tubular adenomas, the most prevalent kind of polyp in the colon and rectum, are not just benign growths. They are the key to understanding the risk of developing colorectal cancer. These growths, usually tiny and mushroom-shaped in the colon's epithelial lining, may indicate a risk of developing cancer in the future. According to research, an adenoma's risk of developing into colorectal cancer increases with the amount of time it stays in the colon untreated.

The vast majority of adenomas do not progress to malignancy and remain benign. Some of these adenomas, however, experience a sequence of genetic alterations that allow them to develop into cancer. The rate at which this transformation occurs can vary greatly, making it a challenge for clinicians to assess which adenomas are at high risk for cancer.

The Adenoma-Carcinoma Sequence

The lengthy, multi-step process known as the "adenoma-carcinoma sequence" is how benign tubular adenomas progress to colorectal cancer. Genetic mutations build up inside the adenoma's cells over time, leading to aberrant growth patterns and the possibility of cancer. This sequence is significantly influenced by several important genetic changes, including mutations in the APC and KRAS genes. Some adenomas have dysplasia, which is characterised by aberrant cell shapes and accelerated cell division rates, which indicate possible cancer risk.

It is essential to comprehend the molecular underpinnings of this development to more precisely identify adenomas that have the highest propensity to develop into cancer. Patients' overall prognosis can be improved with early detection since the right therapies can be taken to stop cancer from developing.

What Are Molecular Biomarkers?

Biological indications known as molecular biomarkers can reveal details about the occurrence, course, or risk of several diseases, including cancer. Blood tests, stool samples, tissue biopsies, and other biological samples can all contain these indicators. Molecular biomarkers can provide information on genetic abnormalities, changes in gene expression, and other biochemical changes that indicate a higher risk of colorectal adenomas progressing to cancer.

Clinicians can use biomarkers as prediction tools to assist them in making better decisions about treatment and surveillance plans. For example, a biomarker profile displaying particular genetic abnormalities may suggest a greater risk of adenoma progression, requiring early management or more frequent surveillance. The use of biomarkers in clinical practice could completely transform colorectal cancer screening and prevention.

Key Molecular Biomarkers for Tubular Adenoma Risk

KRAS Gene Mutations

The KRAS gene is essential for controlling the division and development of cells. Advanced adenomas and colorectal cancer are frequently linked to mutations in KRAS. These mutations cause signalling pathways to become active, which encourages unchecked cell division, a defining feature of malignant growth. The likelihood that a tubular adenoma would develop to cancer is greatly increased when KRAS mutations are present. Consequently, identifying KRAS mutations in adenomas can be crucial in determining the probability of malignancy.

APC Gene Mutations

The APC gene controls cell division and inhibits the proliferation of aberrant cells. Many adenomas have mutations in APC, which are among the first occurrences in the adenoma-carcinoma sequence. A lack of cell cycle regulation brought on by these mutations permits aberrant cell proliferation. Therefore, the existence of APC mutations in a tubular adenoma may suggest a possible malignant route. APC mutations are therefore a crucial diagnostic for early detection and risk assessment.

TP53 Gene Mutations

The "guardian of the genome" is the TP53 gene, essential for stopping faulty cell development.   It accomplishes this by controlling the cell cycle and inducing cell death in the case of DNA damage. The protective role of TP53 is undermined by mutations, which permit faulty cells to multiply unregulated. Larger adenomas and those with high-grade dysplasia are more likely to have TP53 mutations, which increases the likelihood that they may develop into cancer.

Microsatellite Instability (MSI)

Defects in the DNA mismatch repair system, which typically fixes mistakes made during DNA replication, are called microsatellite instability (MSI). When this repair pathway is disrupted, microsatellite DNA sections become unstable, causing mutations to accumulate. Although MSI can also be present in certain spontaneous adenomas, it is frequently observed in hereditary colorectal cancer syndromes. MSI is an important biomarker for early detection because MSI-positive adenomas may suggest a genetic predisposition to colorectal cancer.

DNA Methylation Markers

DNA methylation is the process of adding chemical changes to the DNA molecule that affect gene expression. Precancerous adenomas frequently exhibit abnormal methylation patterns, which may indicate a higher risk of cancer. Higher-risk adenomas have been linked to particular methylation markers, such as those in the hMLH1 and MGMT genes. One noninvasive method of determining the risk of adenoma is to look for these methylation alterations in tissue or stool samples.

Inflammatory Markers

Adenoma progression risk can be evaluated using specific inflammatory biomarkers, and chronic inflammation is a proven risk factor for colorectal cancer. Patients with inflammation frequently have higher levels of proteins including C-reactive protein (CRP) and cytokines, and their presence in adenoma tissue may suggest a higher risk of cancer. Prolonged inflammation in the colon can increase the risk of developing cancer by causing DNA damage and fostering an environment that is conducive to tumour growth.

How Are These Biomarkers Used in Practice?

Risk Assessment in Colonoscopy

The most effective method for identifying adenomas continues to be colonoscopies. However, a more precise risk assessment would be possible if colonoscopy and molecular biomarkers are combined. This would enable medical professionals to identify high-risk patients requiring more regular monitoring. To prevent the development of cancer, for example, the presence of particular genetic mutations or methylation markers in a biopsy may lead to the excision of adenomas sooner or more stringent monitoring.

Non-Invasive Testing

Blood and stool are non-invasive samples from which certain molecular biomarkers can be found. For instance, stool samples can measure MSI and DNA methylation indicators, giving high-risk patients an alternative to standard colonoscopies. Early detection and intervention may result from this, especially for those reluctant to have intrusive treatments done. Through earlier and more frequent screenings, non-invasive biomarker testing may help lower the burden of colorectal cancer.

Personalized Treatment Strategies

Finding high-risk molecular indicators in adenomas may open the door to more individualised treatment plans. Patients who exhibit particular genetic patterns in their adenomas may benefit from:

1. More regular colonoscopies and heightened surveillance
2. Lifestyle modifications to lower the risk of cancer, such as dietary adjustments or physical activity
3. Targeted treatments that target particular genetic changes

Healthcare professionals can improve patient outcomes and reduce the chance of cancer progression by customising treatment and monitoring regimens based on each patient's unique biomarker profile.

Challenges and Future Directions

Cost and Availability

Although molecular biomarker testing has great potential, many patients still find it expensive and inaccessible. Genetic testing and analysis can also be quite expensive, and access to these tests may be restricted in many areas. Although widespread application of these tests is still a barrier, researchers are attempting to make them more accessible and cheap.

Biomarker standardisation

Although many biomarkers have been found in investigations, not all are prepared for clinical application. More research is required to create clear recommendations for interpreting biomarker data and to standardise which biomarkers should be routinely evaluated. Testing and result interpretation must be consistent for biomarker-based risk assessments to be accurate and valuable.

Including Biomarkers in Programs for Screening

Current colorectal cancer screening programs mostly rely on colonoscopy and stool-based testing. However, for low-risk individuals, adding molecular biomarker testing to these programs may improve early detection and reduce pointless treatments. Careful preparation and cooperation between researchers, physicians, and legislators would be necessary for this integration.

Conclusion

Patients with tubular adenomas can have their risk of colorectal cancer evaluated with the help of molecular biomarkers. Biomarkers let physicians make more precise risk assessments, resulting in earlier interventions and better patient outcomes, by identifying genetic and biochemical alterations that indicate a higher chance of developing cancer. Colorectal cancer screening and prevention could be completely transformed by continued research and developments in biomarker technology, even though issues with cost, accessibility, and standardisation still exist.

These technologies could eventually be included into standard screening procedures as our knowledge of molecular biomarkers advances, which would lessen the incidence of colorectal cancer and increase patient survival rates globally.